title: Tenoxicam versus lynestrenol-ethinyl estradiol treatment of dysfunctional uterine bleeding cases during adolescence.
abstract: BACKGROUND
  The purpose of this study was to compare the effectiveness of tenoxicam versus lynestrenol-ethinyl estradiol (L-EE) in the treatment of severe cases of dysfunctional uterine bleeding (DUB) during adolescence.
  
  
  METHODS
  Forty-eight patients with objective DUB completed a randomized comparative trial of treatment with tenoxicam (20 mg daily, n = 23) or L-EE (1 tablet containing 0.05 mg + 2.5 mg, respectively, 3 times daily, n = 25). Treatment was given during menorrhagia until bleeding ceased. Mean age of the patients was 13.74 +/- 2.1 years (range, 11-18 years).
  
  
  RESULTS
  A significantly higher level of hematocrit (35.9% v 32.6%, t = 2.1, P = 0.0217) and hemoglobin (11.5 v 10.4 g%, t = 1.7, P = 0.0495), and significantly less hospitalization (5.75 v 8.33 days, t = 2.45, P = 0.0106) was seen in the tenoxicam group in comparison to L-EE group after completion of the treatment. Three patients were submitted to curettage and seven to transfusion in the group receiving L-EE, but no patients in the tenoxicam group required these procedures.
  
  
  CONCLUSIONS
  Tenoxicam is considered an effective medication for the management of DUB during adolescence.
authors.affiliation: First Department of Obstetrics and Gynecology, Alexandra Hospital, Athens, Greece.
authors.forename: G
authors.initials: G
authors.lastname: Creatsas
authors.forename: E
authors.initials: E
authors.lastname: Cardamakis
authors.forename: E
authors.initials: E
authors.lastname: Deligeoroglou
authors.forename: E
authors.initials: E
authors.lastname: Hassan
authors.forename: V
authors.initials: V
authors.lastname: Tzingounis
mesh_terms: D000293:Adolescent; D000704:Analysis of Variance; D002648:Child; D003277:Contraceptives, Oral, Combined / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007902:Length of Stay / Q000706:statistics & numerical data; D008234:Lynestrenol / Q000627:therapeutic use*; D008595:Menorrhagia / Q000097:blood / Q000188:drug therapy*; D008656:Mestranol / Q000627:therapeutic use*; D010894:Piroxicam / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D003277:Contraceptives, Oral, Combined; D016861:Cyclooxygenase Inhibitors; D004338:Drug Combinations; D006454:Hemoglobins; D010894:Piroxicam; C002746:Noracycline; D008656:Mestranol; D008234:Lynestrenol; C032801:tenoxicam